Combinational immunological checkpoint inhibitors for non-small cell lung cancer
10.3760/cma.j.issn.1673-422X.2017.12.013
- VernacularTitle:联合免疫检查点抑制剂治疗非小细胞肺癌
- Author:
Yingli YUAN
1
;
Kewei MA
Author Information
1. 吉林大学第一医院肿瘤中心
- Keywords:
Carcinoma,non-small-cell lung;
Immunosuppressive agents;
Therapy
- From:
Journal of International Oncology
2017;44(12):933-936
- CountryChina
- Language:Chinese
-
Abstract:
Immunological checkpoint inhibitors have become one of the major treatment options for patients with advanced non-small cell lung cancer (NSCLC).Despite patients with NSCLC show the superiority of standard chemotherapy in different disease settings,the response rate is still low in patients with high macromolecule selection for chemotherapy tolerance and gene mutation.This is related to the complexity and dynamics of known limited biomarkers and tumor microenvironment.Different methods of tumor cells to evade the immune system used to lay the foundation for the new combination strategy.Combination therapy not only improves the efficacy of treatment,but also makes the objective response rate improved significantly.
